A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors
Mark W. Kieran*, Susan Chi, Stewart Goldman, Arzu Onar-Thomas, Tina Young Poussaint, Sridhar Vajapeyam, Frederic Fahey, Shengjie Wu, David C. Turner, Clinton F. Stewart, Marsha Moses, Roger J. Packer, Regina Jakacki, Anu Banerjee, James M. Boyett, Maryam Fouladi, Larry Kun
Dive into the research topics of 'A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors'. Together they form a unique fingerprint.